Shire acquires Meritage for potential $245m
This article was originally published in Scrip
Executive Summary
Shire is continuing its 2015 M&A shopping spree by acquiring Meritage Pharma for $70m upfront in order to boost its late-stage rare disease pipeline.
You may also be interested in...
Shire's Ornskov: The Modest Pediatrician With Fierce Corporate Ambition
Since becoming CEO of Shire in April 2013, Flemming Ornskov has overseen around $50bn in M&A deals. He steered the company through the ultimately abortive takeover by AbbVie and walked away with a break fee of $1.6bn, going on to consummate instead Shire’s $32bn acquisition of Baxalta earlier this year. He spoke to Scrip about his vision and values.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.